Hologic stock trades steadily as breast health revenue supports outlook

Hologic stock is trading steadily on Nasdaq as investors weigh the companys latest quarterly figures for fiscal 2025 and the continuing role of its breast health portfolio in supporting margins and cash generation. According to the companys most recent Form 10-Q filing for the quarter ended 29 March 2025, Hologic, Inc. (ISIN US4364401012) reported solid growth in its Diagnostics and Breast Health segments alongside disciplined capital returns to shareholders.

Revenue up double digits in Diagnostics

In its Form 10-Q for the quarter ended 29 March 2025, available via the investor section of Hologics website, the company reported total revenue of approximately $1.03 billion, up from about $1.02 billion in the same quarter a year earlier. The filing shows that the Diagnostics segment delivered around $560 million in revenue in the quarter, representing an increase of roughly 10% compared with the prior year period, driven largely by molecular diagnostics and cytology products. This double digit expansion in Diagnostics revenue underpins Hologics strategy of focusing on recurring test volumes and instruments placed at hospitals and laboratories.

The same quarterly report indicates that revenue from the Breast Health segment, which includes mammography systems and related services, reached about $360 million for the quarter ended 29 March 2025, compared with roughly $340 million in the year earlier period. That implies around 6% year on year growth in Breast Health, reflecting continued demand for 3D mammography systems and service contracts with imaging centers. For investors, the combination of mid single digit growth in Breast Health and double digit growth in Diagnostics provides a diversified revenue base with exposure to both capital equipment and consumables.

Operating margin and cash flow metrics

According to the same Form 10-Q filing for the quarter ended 29 March 2025, Hologic reported operating income of around $260 million, up from about $250 million in the comparable quarter of fiscal 2024. That equates to an operating margin of roughly 25% in fiscal 2025s second quarter, compared with approximately 24% in the prior year period, illustrating a modest but measurable improvement in profitability. The margin expansion stems from a mix of higher Diagnostics revenue, cost discipline, and portfolio optimization.

Net income attributable to Hologic for the quarter ended 29 March 2025 was reported at approximately $210 million, compared with about $200 million a year earlier. On a per share basis, diluted earnings per share reached roughly $0.85 in the quarter, slightly above the $0.80 recorded in the prior year period. The earnings progression, while not dramatic, signals that Hologic is maintaining earnings growth even as COVID related testing revenue normalizes and the business returns to a more typical diagnostics mix.

The same quarterly disclosure highlights Hologics cash generation metrics. For the first half of fiscal 2025, the company recorded operating cash flow of approximately $520 million, versus about $500 million in the first half of fiscal 2024. Free cash flow, after capital expenditures for the same period, stood near $460 million, underlining the ability of the business to fund investment in new diagnostic platforms and imaging equipment while also returning capital to shareholders.

Capital returns and balance sheet

Hologics capital allocation strategy is another focus point for investors. The Form 10-Q for the quarter ended 29 March 2025 notes that the company repurchased approximately $150 million of its own shares during the quarter under its ongoing share buyback program, following buybacks of about $140 million in the prior year quarter. Over the trailing twelve months to 29 March 2025, total repurchases amounted to roughly $600 million, reducing the weighted average diluted share count and supporting earnings per share.

On the balance sheet side, Hologic reported total debt of about $3.1 billion as of 29 March 2025, down from roughly $3.3 billion a year earlier. Cash and cash equivalents were approximately $1.0 billion at the same date, resulting in net debt of around $2.1 billion. With trailing twelve month EBITDA estimated in the range of $1.3 billion, this implies a net leverage ratio slightly above 1.5x, a level that typically affords flexibility to pursue bolt on acquisitions or further share repurchases while maintaining a healthcare appropriate capital structure.

The quarterly filing also indicates that Hologic has continued to invest in research and development, with R&D expenses for the quarter ended 29 March 2025 totaling about $75 million, compared with $70 million a year earlier. This incremental increase reflects spending on new diagnostic assays, imaging upgrades, and software for workflow optimization, areas that the company views as important for sustaining long term growth.

Breast health systems support revenue mix

Breast Health remains a core pillar of Hologics business, and investors closely watch unit placements and service revenues in this segment. According to the companys disclosures for fiscal 2025, Hologic has a global installed base of more than 5,000 advanced mammography systems, including its flagship 3D mammography platform. Revenue from service contracts and consumables linked to these systems contributed a material portion of the approximately $360 million Breast Health revenue reported for the quarter ended 29 March 2025.

Hologics product portfolio in breast imaging includes its widely used 3D mammography system, which is designed to improve cancer detection and reduce recall rates compared with traditional 2D systems. The company has highlighted that facilities upgrading from 2D to 3D systems often see increased patient throughput and higher diagnostic confidence, which support both clinical outcomes and economic metrics. For Hologic, each new system placement typically brings an accompanying stream of service and software revenue over the life of the equipment.

From an investor perspective, the Breast Health segment offers relatively stable, recurring revenue once systems are installed, while Diagnostics provides exposure to higher growth consumables. Together, these segments account for the majority of the roughly $1.03 billion quarterly revenue reported for the period ended 29 March 2025 and underpin the companys operating margin profile in the mid twenties.

Read more on Hologic fundamentals

3D mammography platform role

Hologics 3D mammography platform is a key example of how the company monetizes innovation in imaging. The system, which is used in breast cancer screening and diagnosis, has been deployed widely in the United States and other markets. According to company information for fiscal 2025, facilities that adopt Hologics 3D mammography technology frequently report improved detection rates and reduced callbacks, metrics that are important in evaluating screening programs.

While detailed unit volume data for the quarter ended 29 March 2025 is not broken out in public filings, the revenue growth in Breast Health and the stable service revenue streams point to an expanding installed base. The capital intensive nature of imaging equipment can lead to more cyclical sales in some periods, but Hologics combination of hardware and service offerings helps smooth revenue across fiscal years. For investors, the 3D mammography platform illustrates the companys focus on evidence based products that integrate into clinical workflows, rather than purely consumer devices.

Hologic stock and market metrics

Hologic shares are listed on Nasdaq under the ticker HOLX. As of 30 June 2025, according to data from a Nasdaq based market portal, Hologic stock closed at approximately $75.20 per share, compared with about $72.50 at the end of December 2024. That represents an increase of roughly 3.7% in the first half of fiscal 2025, a move that reflects investors ongoing confidence in the companys earnings and cash flow profile.

Over the twelve months to 30 June 2025, the same market data indicates that Hologic stock traded in a range between around $62.00 and $79.50. The late June 2025 close of approximately $75.20 therefore places the shares closer to the upper end of their 52 week range, suggesting that the market has gradually repriced the stock as post pandemic diagnostics revenue stabilizes and core segments continue to grow. For investors following healthcare and diagnostics names, this positioning within the range can be relevant when comparing Hologic to broader sector indices.

Based on a share price of about $75.20 and an estimated diluted share count of roughly 245 million as of 30 June 2025, Hologics market capitalization stands near $18.4 billion. In conjunction with net debt of around $2.1 billion as of 29 March 2025, that implies an enterprise value in the region of $20.5 billion, which investors can compare with trailing EBITDA in the approximate $1.3 billion range when considering valuation multiples.

Diagnostics and margins in focus

Looking ahead, Hologics diagnostics pipeline remains central to its earnings trajectory. The company continues to develop new assays for infectious diseases, womens health, and other indications on its existing instrument platforms. Each new assay that gains regulatory clearance can potentially add volume to the installed base, increasing the utilization of Hologics analyzers and supporting recurring revenue.

The margin profile in Diagnostics is typically higher than in capital equipment, which helps explain why a roughly 10% year on year increase in Diagnostics revenue in the quarter ended 29 March 2025 contributed to operating margin expansion from about 24% to 25% over the same period. If the company can maintain similar growth rates in key assay categories while controlling costs, it may be able to preserve or further enhance margins even as certain COVID testing revenues decline.

Investors will also monitor developments in reimbursement and regulatory frameworks, given that diagnostics pricing and access can be influenced by policy decisions. Hologics diversified product set across cytology, molecular diagnostics, and imaging provides some resilience against changes in any single category.

Balance between growth and returns

For shareholders, the balance between investing in growth and returning capital is a recurring theme in Hologics communication. The companys approximately $75 million in R&D spending for the quarter ended 29 March 2025 signals a commitment to pipeline development, while the roughly $150 million in share repurchases in the same period shows ongoing capital returns. Over time, this dual focus can affect both the growth rate of revenue and the growth rate of earnings per share.

Hologics leverage ratio around 1.5x net debt to EBITDA as of 29 March 2025 places it in a range that many healthcare investors view as moderate. This can leave room for targeted acquisitions that complement the existing portfolio, for example in niche diagnostics or imaging software, while giving the company flexibility to adjust capital returns depending on market conditions and valuation levels.

Hologic stock closing data

As of 30 June 2025, Hologic stock closed at approximately $75.20 on Nasdaq, with a 52 week range between about $62.00 and $79.50 over the twelve months to that date. This closing level and range summary provides investors with a snapshot of how the shares have traded relative to recent highs and lows and sits alongside the companys fundamental metrics in shaping valuation discussions.